Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine.
We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI). Nine patients with POTS and six patients with OI stood for up to 1 hour while their HR and BP were monitored. Patients received on separate days, midodrine 10 mg 1 hour before testing, octreotide 0.9 micro g/kg 8 minutes before testing or combination therapy. Standing time in the patients with POTS was 41.2 +/- 8.4 minutes and not improved by midodrine or octreotide, but increased to 56.3 +/- 2.7 (P < 0.01) minutes following combination therapy. The standing heart rate in POTS, 114 +/- 0.7 bpm, was suppressed by midodrine 92.8 +/- 0.7 (P < 0.001), octreotide 90.6 +/- 0.78 (P < 0.001), and combination therapy 84.7 +/- 0.7 (P < 0.001). Combination therapy was better than monotherapy (P < 0.001) but only for the first 10 minutes of standing. Standing time of 36.3 +/- 3.5 minutes in the patients with OI improved with midodrine, octreotide and combination therapy (55.5 +/- 3.1, 56.5 +/- 3.5, and 56.6 +/- 3.3, respectively, P < 0.05 for each). Standing heart rate in OI was 100 +/- .76 bpm; following midodrine it was 80.3 +/- .69 (P < 0.05), following octreotide it was 84.8 +/- .86, and following combination therapy it was 71.2 +/- .9 (P < 0.01). The RR interval versus time area under the curve (The Orthostatic Index) was 21.1 +/- 4 in patients with OI. After midodrine it was 41.4 +/- 3.5 (P < 0.01), after octreotide 40.3 +/- 3.8 (P < 0.01) and after the combination it was 47.3 +/- 4.6 (P < 0.001). Midodrine and octreotide suppressed tachycardia in POTS and improved standing times in OI. The two drugs had similar potencies; combination therapy was not significantly better than monotherapy.
Hoeldtke
Robert D
RD
Dept of Medicine, West Virginia University, One Medical Center Drive, Morgantown, WV 26506-9159, USA. rhoeldtke@hsc.wvu.edu
Bryner
Kimberly D
KD
Hoeldtke
Martin E
ME
Hobbs
Gerald
G
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003627:Data Interpretation, Statistical; D004244:Dizziness / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D008879:Midodrine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015282:Octreotide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011187:Posture / Q000502:physiology*; D013577:Syndrome; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology*; D013997:Time Factors; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D014662:Vasoconstrictor Agents; D008879:Midodrine; D015282:Octreotide